Cargando…
Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis
Eosinophils play an important pathogenetic role in the development of eosinophilic granulomatosis with polyangiitis (EGPA). EGPA has long been treated with systemic corticosteroids and immunosuppressive agents. However, in recent years, biologic agents targeting eosinophils (anti-IL-5 antibody; mepo...
Autores principales: | Matsuno, Osamu, Minamoto, Seijiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637965/ https://www.ncbi.nlm.nih.gov/pubmed/36353062 http://dx.doi.org/10.1016/j.rmcr.2022.101763 |
Ejemplares similares
-
Retropharyngeal edema: A rare manifestation of eosinophilic granulomatosis with polyangiitis
por: Matsuno, Osamu, et al.
Publicado: (2021) -
Flare of eosinophilic granulomatosis with polyangiitis related to pregnancy: Case report and review of the literature
por: Matsuno, Osamu, et al.
Publicado: (2018) -
Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
por: Martínez-Rivera, Carlos, et al.
Publicado: (2021) -
Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021) -
COVID-19 in a Patient With Severe Eosinophilic Asthma on Benralizumab Therapy: A Case Report and Review of Literature
por: Matsuno, Osamu, et al.
Publicado: (2021)